| Liu, Jihong |
NCT03687606: Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) |
|
|
| Recruiting | 4 | 210 | RoW | Human Chorionic Gonadotropin, hCG, human menopausal gonadotropin, hMG | Tongji Hospital | Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome, Infertility | 10/24 | 10/25 | | |
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 393 | RoW | IMP4927, Placebos | Impact Therapeutics, Inc. | Ovarian Cancer | 02/22 | 12/22 | | |
| Recruiting | 3 | 700 | RoW | NACT (Paclitaxel + Cisplatin or carboplatin), radical surgery | Sun Yat-sen University | PFS, OS, Quality of Life | 12/22 | 12/22 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT02859038: Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) |
|
|
| Recruiting | 3 | 488 | RoW | Upfront cytoreductive surgery, Primary debulking surgery, PDS, Interval debulking surgery, NACT-IDS | Shanghai Gynecologic Oncology Group | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/23 | 06/23 | | |
SHR-1701-III-309, NCT05179239: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer |
|
|
| Recruiting | 3 | 572 | RoW | SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Cervical Cancer | 03/24 | 05/25 | | |
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 498 | RoW | QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin | Qilu Pharmaceutical Co., Ltd. | METASTATIC CERVICAL CANCER | 09/24 | 07/25 | | |
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
NCT05737303: Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 538 | RoW | nab-paclitaxel combined with carboplatin, paclitaxel combined with carboplatin | Women's Hospital School Of Medicine Zhejiang University, Jiaxing Maternity and Child Health Care Hospital, Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Sun Yat-sen University, Qilu Hospital of Shandong University, Ningbo No. 1 Hospital, Ningbo Women & Children's Hospital, Sir Run Run Shaw Hospital | Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV | 12/24 | 12/27 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
NCT04864782: QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer |
|
|
| Terminated | 2/3 | 46 | RoW | QL1604, PD-1 monoclonal antibody, Paclitaxel injection, Cisplatin/Carboplatin | Qilu Pharmaceutical Co., Ltd. | Cervical Cancer | 09/22 | 11/23 | | |
ANNIE, NCT04376073: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Niraparib, Anlotinib | Jihong Liu | Platinum-resistant Ovarian Cancer | 12/21 | 03/22 | | |
NCT05557565: A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer |
|
|
| Recruiting | 2 | 150 | RoW | QL1706 | Qilu Pharmaceutical Co., Ltd. | Cervical Cancer | 10/22 | 06/23 | | |
KEYNOTE 826, NCT04799639: Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer |
|
|
| Completed | 2 | 47 | RoW | Sindilimab +paclitaxel+ cisplantin | Sun Yat-sen University | Cervical Cancer, Chemotherapy Effect, Programmed Cell Death 1 Receptor / Antagonists & Inhibitors, Neoadjuvant Therapy | 06/24 | 06/24 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
AK3280-2002, NCT05424887: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | 2 | 105 | RoW | AK3280, Placebo | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Idiopathic Pulmonary Fibrosis | 07/24 | 10/24 | | |
| Recruiting | 2 | 100 | RoW | SHR-A2102 for injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Gynecological Malignancy | 08/25 | 10/26 | | |
NCT05434897: A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | AK3280 Cream, AK3287, Placebo cream | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Hypertrophic Scar | 07/23 | 11/23 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05779163: A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 468 | RoW | LBL-033 for Injection, LBL-033 | Nanjing Leads Biolabs Co.,Ltd | Advanced Malignant Tumors | 03/26 | 03/26 | | |
TIL-Cx, NCT04443296: Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma |
|
|
| Active, not recruiting | 1 | 10 | RoW | CCRT+TIL | Sun Yat-sen University | Cervical Carcinoma | 12/21 | 12/22 | | |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
NCT02642471: Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) |
|
|
| Active, not recruiting | N/A | 1080 | RoW | no systematic pelvic lymphadenectomy | Sun Yat-sen University | Cervical Cancer, Surgery, Quality of Life | 12/24 | 12/24 | | |
| Recruiting | N/A | 590 | RoW | Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy | Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital | Endometrial Cancer Stage I, Endometrial Cancer Stage II | 12/24 | 01/27 | | |
RWS-MTB, NCT06781151: A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB |
|
|
| Recruiting | N/A | 200 | RoW | | Sun Yat-sen University | Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent | 12/26 | 06/27 | | |
SYSUGO-005, NCT02624531: Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(/CSEM009) |
|
|
| Recruiting | N/A | 60 | RoW | Taxane, cisplatin, radical trachelectomy, simple trachelectomy, conization, sentinel node biopsy | Sun Yat-sen University | Cervical Cancer | 11/25 | 11/25 | | |
| Recruiting | N/A | 656 | RoW | Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy, Comprehensive staging surgery with no Lymphadenectomy | Sun Yat-sen University | Ovarian Cancer, Lymphadenectomy | 12/25 | 12/28 | | |
